Sugi Predict

Sugi Predict / Targets / BPHL

BPHL

Serine hydrolase BPHL · Q86WA6 · BPHL on Sugi Atlas →

0 patent compounds predicted against BPHL, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to BPHL by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluation of the Effect of Garcinia in Combination With Chromium on the Clinical Outcomes of Patients With LUTS/BPH PHASE2UNKNOWN
The Effect of Traditional Chinese Medicine on Benign Prostatic Hyperplasia PHASE1/PHASE2COMPLETED
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia PHASE2RECRUITING
Office Based Transperineal Laser Ablation for Benign Prostatic Hyperplasia HYPERPLASIA PHASE1UNKNOWN
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia nanCOMPLETED
Intraprostatic Injection of Tranexamic Acid Decrease Blood Loss During Monopolar TURP nanUNKNOWN
Evaluation of the Impact of Preoperative Pelvic Floor Exercise on Incontinence After Laser Enucleation of the Prostate: a Feasibility Study. nanACTIVE_NOT_RECRUITING
HoLEP vs mTURP in Management of Benign Prostatic Hyperplasia nanCOMPLETED
Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms nanCOMPLETED
Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients Who Completed 12 Months of Follow-Up Post Implantation (Continuation Study for Study BM-011-IL) nanACTIVE_NOT_RECRUITING
Urinary Incontinence After Endoscopic Prostatectomy nanCOMPLETED
Electromagnetic Field Therapy Versus Aerobic Exercise on Prostatic Function in Elderly With Benign Prostatic Hyperplasia nanENROLLING_BY_INVITATION
HoLEP in Management of BPH Patients With Predominant Voiding vs Storage LUTS: A Comparative Retrospective Study nanCOMPLETED
Benign Prostate Surgery and QOL and Sexual Function nanUNKNOWN
Outcomes of Water Vapor Thermal Therapy (REZUM) in Management of Symptomatic Patients With Benign Prostatic Enlargement nanUNKNOWN
Local Anesthesia With Schelin Catheter in Rezum Treatment: a Randomized Controlled Trial nanRECRUITING
Standardization of Prostatic Resection by Virtual Computational Reconstruction and Computational Flow Dynamics nanCOMPLETED
TURP Inpatient With Underactive Bladder With BOO nanRECRUITING
The Effects of Holmium Laser Enucleation and Thulium Laser Enucleation on Continence, Urethral Stricture, and Sexual Function in Benign Prostatic Hyperplasia nanNOT_YET_RECRUITING
Prostate Enucleation With Intravesical Botox Injections in Treating BPH and Bladder Overactivity nanUNKNOWN
The Risk Factor and Outcome of Transient Incontinence After Prostate Enucleation Surgery nanUNKNOWN
EEP in Patients With Urodynamically Proven DU/DA nanNOT_YET_RECRUITING
Prostate Artery Embolization: Single Center Experience nanUNKNOWN
To Identify Potential New Urine Markers for the Screening of Prostate Cancer nanRECRUITING
Bipolar Transurethral Enucleation Versus Resection in the Treatment of Benign Prostatic Hyperplasia: a Comparative Study nanCOMPLETED
Low Energy HoLEP on IPSS nanUNKNOWN
Prostate Cancer Antigen 3 (PCA-3) Gene Project nanCOMPLETED
Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin. nanRECRUITING
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy nanRECRUITING
Preoperative Anxiety and Surgical Fear in Holmium Laser Enucleation of the Prostate and Transurethral Resection of the Prostate Patients With Benign Prostatic Hyperplasia nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BPHL binder may also engage these)

ProteinNameSimilarity
Q8R164 — 0.989 Q8R164 →
P13255 — 0.957 P13255 →
Q29513 — 0.956 Q29513 →
GNMT Glycine N-methyltransferase 0.956 landscape →
Q9QXF8 — 0.954 Q9QXF8 →
P23965 — 0.953 P23965 →
Q5FVD6 — 0.953 Q5FVD6 →
D3ZLY0 — 0.952 D3ZLY0 →
EPM2A Laforin 0.952 landscape →
DDO D-aspartate oxidase 0.951 landscape →
Q29555 — 0.950 Q29555 →
Q5F477 — 0.950 Q5F477 →
ECI1 Enoyl-CoA delta isomerase 1, mitochondrial 0.950 landscape →
Q5R514 — 0.950 Q5R514 →
Q96RR1 — 0.949 Q96RR1 →
Q6NYU2 — 0.949 Q6NYU2 →
P10868 — 0.949 P10868 →
Q6P4H8 — 0.948 Q6P4H8 →
Q5R5F8 — 0.948 Q5R5F8 →
Q9H4I8 — 0.948 Q9H4I8 →
Q0J0A4 — 0.948 Q0J0A4 →
O35969 — 0.947 O35969 →
Q5RAF1 — 0.947 Q5RAF1 →
A3KCL7 — 0.947 A3KCL7 →
Q64323 — 0.947 Q64323 →
Q8CG45 — 0.947 Q8CG45 →
Q5H879 — 0.946 Q5H879 →
Q91W86 — 0.946 Q91W86 →
Q96MS3 — 0.946 Q96MS3 →
Q08C93 — 0.946 Q08C93 →